By InvitationPhase 3

To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

South Korea125 participantsStarted 2025-04-22

Plain-language summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 19 * Patients with Essential Hypertension and Primary Hypercholesterolemia Exclusion Criteria: * Patients with differences between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP * Patients with mean sitSBP ≥ 180 mmHg or mean sitDBP ≥ 110 mmHg

What they're measuring

Low density lipoprotein cholesterol (LDL-C)

Timeframe: baseline and week 8

Mean sitting systolic blood pressure (MSSBP)

Timeframe: baseline and week 8

Trial details

NCT IDNCT06646354

SponsorHyundai Pharm

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-05-19

View on ClinicalTrials.gov More Hypertension trials